Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

EST: Adds comments from Seeking Alpha analyst BioCGT Investor Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in ...

And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity. Even with Eli Lilly's Mounjaro and ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The company's older weight loss drug, liraglutide, is marketed as Victoza for diabetes and Saxenda for weight loss. Because Eli Lilly's tirzepatide did not hit the market as Mounjaro for diabetes ...

Let's look at five pharma and drug companies ... by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus. Here's why they view Eli Lilly (NYSE: LLY), Novo ...